Medy-Tox
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Medy-Tox is a South Korean pharmaceutical and biotechnology company best known for making botulinum toxin products, injectable treatments used to reduce wrinkles and address certain medical conditions.
Its products are used by medical professionals in aesthetic and therapeutic settings. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Medy-Tox in five facts
What does Medy-Tox do?
Medy-Tox is a South Korean pharmaceutical and biotechnology company best known for making botulinum toxin products, injectable treatments used to reduce wrinkles and address certain medical conditions.
Where is Medy-Tox listed and in which sector?
Medy-Tox (Korean name: 메디톡스) trades under KRX code 086900 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Medy-Tox?
Its market capitalisation was US$378.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Medy-Tox's latest annual revenue and operating profit?
For fiscal year 2025, Medy-Tox reported revenue of US$186.6M, operating profit of US$12.8M and net income of US$11.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 8.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Cash/in-kind dividend decision
Medy-Tox updated its declared cash dividend of US$0.89 per share, equal to about 1.8% of the recent share price.
Dividend · Oct 16 · 2 versions - DisclosureOct 14
- [Amended] Share cancellation decisionSep 30
- Report on securities held by executives/major shareholdersSep 16
- Operating results (consolidated) (preliminary) (fair disclosure)
Medy-Tox filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$48.5M (+11.4% year on year), operating profit of US$3.36M (−24.6% year on year) and net income of US$2.21M (−61.7% year on year).
Earnings · Aug 10 - Treasury share acquisition: results reportTreasury Shares · Jun 17
- Material event report (treasury share acquisition)
Medy-Tox disclosed a plan to buy back its own shares worth US$3.28M, about 1.0% of its market value.
Treasury Shares · Jun 9 - Operating results (consolidated) (preliminary) (fair disclosure)
Medy-Tox filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$40.6M (−5.1% year on year), operating profit of US$4.94M (+34.6% year on year) and net income of US$5.28M (+135.7% year on year).
Earnings · May 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Medy-Tox reported consolidated results for FY2025: revenue of US$168M (+8.2% year on year), operating profit of US$11.7M (−15.3% year on year) and net income of US$10.5M (−3.8% year on year).
Earnings · Mar 12 - Treasury share acquisition: results reportTreasury Shares · Feb 13
- Material event report (treasury share acquisition)Treasury Shares · Jan 28